Results 241 to 250 of about 50,613 (304)

Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics. [PDF]

Arthritis Res Ther
Bentvelzen MLM, El Bouhaddani S, Spierings J, Concepcion AN, Vonkeman HE, Mooij SC, Schipper LG, Herman A, Vreugdenhil SA, TOFA-PREDICT author group, Mastbergen SC, Welsing PMJ.   +11 more
europepmc   +1 more source

Use Patterns of Novel Janus Kinase Inhibitors After the First Safety Alerts: A Nationwide Register‐Based Time Series Analysis

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 6, June 2026.
ABSTRACT Purpose Janus kinase inhibitors (JAKi) are medicines used to treat inflammatory rheumatic musculoskeletal diseases (IRMDs) and inflammatory bowel diseases (IBDs). In Europe, JAKis received marketing authorisation in 2017 for rheumatoid arthritis.
Jarno Rutanen, Pekka Heino, Kati Sarnola, Terhi Kurko   +3 more
wiley   +1 more source

Impact of biologic class and treatment line on psoriatic arthritis risk in psoriasis: a population-based cohort study. [PDF]

RMD Open
Watad A, Elizur Y, Hen O, David P, Patt YS, Gendelman O, Nachman A, Zabotti A, Lidar M, McGonagle D, Amital H.   +10 more
europepmc   +1 more source

Variable Selection for Illness‐Death Processes Under Dual Observation Schemes

Statistics in Medicine, Volume 45, Issue 13-14, June 2026.
ABSTRACT The classical illness‐death process offers a useful framework for studying the progression of chronic disease while jointly modeling death. In many settings the time of disease progression is not observed directly, but progression status is recorded at intermittent assessment times.
Xianwei Li, Liqun Diao, Richard J. Cook
wiley   +1 more source

Correction: Comparative Effectiveness of Bimekizumab and Secukinumab in Patients with Psoriatic Arthritis at 52 Weeks Using a Matching-Adjusted Indirect Comparison. [PDF]

Rheumatol Ther
Mease PJ, Warren RB, Nash P, Grouin JM, Lyris N, Willems D, Taieb V, Eells J, McInnes IB.   +8 more
europepmc   +1 more source

Nanobodies: A Promising Toolkit for Diagnostic Applications

SmartMat, Volume 7, Issue 3, June 2026.
This review focuses on camelid‐derived nanobodies (VHHs) and explains how their small size and high stability support robust diagnostic design. Applications across ELISA, lateral flow assays, and PET/SPECT imaging are summarized, along with clinical progress such as caplacizumab.
Wei Wu, Abid Ali, Li Sun, Jiahao Hu, Lina Hameed, Saba Shafi, Ali Raza, Khuzin Dinislam, Wenjing Xing, Long Rong, Jie Lin, Jian Ma   +11 more
wiley   +1 more source

Transcriptomic profiling of secukinumab-treated psoriatic arthritis reveals potential novel response-associated pathways. [PDF]

Rheumatology (Oxford)
Abdul Jalil NA, Chinoy H, Jani M, Barton A, Thompson C, Martin P, Nair N, Bluett J, Outcomes of Treatment in Psoriatic Arthritis Study Syndicate (OUTPASS) .   +8 more
europepmc   +1 more source

Efficacy and Safety of Oral Icotrokinra in Moderate‐to‐Severe Plaque Psoriasis: A Systematic Review, Meta‐Analysis, and Trial Sequential Analysis

International Journal of Dermatology, Volume 65, Issue 6, Page 1144-1154, June 2026.
Meta‐analysis of randomized controlled trials demonstrates that oral icotrokinra significantly improves PASI responses in patients with moderate‐to‐severe plaque psoriasis, with early clinical benefit and a placebo‐comparable safety profile, supported by trial sequential analysis confirming robust and sufficient evidence.
Alhasan Altayf, Munder Lateiresh, Lutfiyah Marwan, Mohamed Yaseen Alfeetouri, Yassine Zouaoui, Muhammed Elhadi   +5 more
wiley   +1 more source

Psychometric Evaluation of the Tagalog Version of Psoriatic Arthritis Quality of Life Questionnaire. [PDF]

Acta Med Philipp
Sarosong RP, Salido EO, Hollings SJ, Grzeda MT.   +3 more
europepmc   +1 more source